ADMA Biologics Inc Forecasted to Post FY2021 Earnings of $0.24 Per Share (NASDAQ:ADMA)

ADMA Biologics Inc (NASDAQ:ADMA) – Stock analysts at Jefferies Financial Group raised their FY2021 earnings per share (EPS) estimates for shares of ADMA Biologics in a note issued to investors on Monday, August 12th. Jefferies Financial Group analyst A. Petrone now forecasts that the biotechnology company will post earnings per share of $0.24 for the year, up from their prior forecast of $0.23. Jefferies Financial Group has a “Buy” rating and a $8.00 price objective on the stock. Jefferies Financial Group also issued estimates for ADMA Biologics’ FY2022 earnings at $0.92 EPS and FY2023 earnings at $1.44 EPS.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $6.56 million for the quarter, compared to the consensus estimate of $4.36 million. ADMA Biologics had a negative return on equity of 273.18% and a negative net margin of 323.54%.

ADMA has been the topic of a number of other reports. Oppenheimer set a $14.00 price objective on ADMA Biologics and gave the company a “buy” rating in a report on Tuesday, June 25th. Dawson James downgraded ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 price objective on the stock. in a report on Monday. Finally, HC Wainwright set a $13.00 price objective on ADMA Biologics and gave the company a “buy” rating in a report on Thursday, May 23rd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $10.17.

NASDAQ ADMA opened at $3.90 on Wednesday. The company has a current ratio of 4.60, a quick ratio of 2.39 and a debt-to-equity ratio of 5.70. The stock’s 50 day moving average is $3.73 and its two-hundred day moving average is $4.03. The company has a market capitalization of $226.37 million, a price-to-earnings ratio of -2.69 and a beta of 2.71. ADMA Biologics has a 1-year low of $2.08 and a 1-year high of $6.96.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of ADMA Biologics by 0.5% in the 4th quarter. BlackRock Inc. now owns 964,349 shares of the biotechnology company’s stock worth $2,305,000 after acquiring an additional 4,577 shares in the last quarter. Raymond James & Associates boosted its holdings in shares of ADMA Biologics by 65.2% in the 4th quarter. Raymond James & Associates now owns 26,871 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 10,610 shares in the last quarter. Private Advisors LLC acquired a new position in shares of ADMA Biologics in the 2nd quarter worth approximately $41,000. Citadel Advisors LLC boosted its holdings in shares of ADMA Biologics by 96.3% in the 2nd quarter. Citadel Advisors LLC now owns 22,187 shares of the biotechnology company’s stock worth $86,000 after acquiring an additional 10,887 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of ADMA Biologics by 25.1% in the 2nd quarter. Jane Street Group LLC now owns 58,374 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 11,711 shares in the last quarter. 38.82% of the stock is currently owned by institutional investors and hedge funds.

In other news, major shareholder Biotest Divestiture Trust sold 5,813,954 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $3.75, for a total value of $21,802,327.50. Following the transaction, the insider now directly owns 4,295,580 shares of the company’s stock, valued at approximately $16,108,425. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Life Sciences Maste Perceptive bought 4,000,000 shares of ADMA Biologics stock in a transaction dated Tuesday, May 21st. The stock was acquired at an average cost of $4.00 per share, for a total transaction of $16,000,000.00. The disclosure for this purchase can be found here. 15.20% of the stock is owned by insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Recommended Story: Street Name

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.